The trial of the treatment has entered a new phase after US President Donald Trump recovered from a serious type of the Wuhan virus illness.

A group of pharmaceutical companies including Japan’s Takeda Pharmaceutical has begun enrolling patients in a global clinical trial for a potential Wuhan virus treatment using convalescent plasma collected from patients who have recovered from the virus.

The National Institute of Allergy and Infectious Diseases in the US is sponsoring the phase 3 trial, which plans to enroll 500 hospitalised patients in the US, Mexico and 16 other countries.

Patients who will be treated with the new drug called hyperimmune intravenous immunoglobulin (H-Ig) will also be given Gilead’s antiviral drug remdesivir, and the results will be compared with those treated with remdesivir and a placebo.

The trial of the treatment has accelerated after US President Donald Trump (74) recovered from a serious type of the Wuhan virus illness with the assistance of these new drugs.

The high toll of daily deaths caused by the Wuhan virus, in the places with a high contamination, put in doubt hypothesis of herd immunity as a resurgence in cases poses fresh challenges to the authorities and the scientists.

The death toll varies significantly from day to day demonstrating no regularity or logical pattern.

The only solution for controlling epidemic is an effective vaccine which may not be available until at least half of the next year or a successful treatment.